83 results
424B5
bna4 o1mrkszbhcp4
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
iaakgcomh3qcm4 ew3
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.2
auuiwll9in0jyz9vdva0
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
EX-4.4
x503r cf3f3b
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
kyo8q
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
pzco67bt5pg9m6cg8c0
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-10.1
8hamkti
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
S-8
EX-99.4
032 ldr80bt0jz7txnk5
2 Feb 24
Registration of securities for employees
4:04pm
8-K/A
EX-99.1
6a8g9k3r
22 Nov 23
Report of Independent Auditors
4:02pm
8-K/A
EX-99.2
8yqgq48
22 Nov 23
Report of Independent Auditors
4:02pm
8-K
EX-3.2
gtu np8mb
4 Oct 23
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
6:56am
424B3
2qt5f9kc
28 Aug 23
Prospectus supplement
9:10am